Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lussier, Yves A ^a,b,c   Khodarev, Nikolai N ^a   Regan, Kelly ^b   Corbin, Kimberly ^a   Li, Haiquan ^b   Ganai, Sabha ^a   Khan, Sajid A ^a   Gnerlich, Jennifer ^a   Darga, Thomas E ^a   Fan, Hanli ^b   Karpenko, Oleksiy ^b   Paty, Philip B ^d   Posner, Mitchell C ^a   Chmura, Steven J ^a   Hellman, Samuel ^a   Ferguson, Mark K ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Illinois at Chicago   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CANCER; OLIGOMETASTASIS; OUTCOME ASSESSMENT; POLYMETASTASIS;

ADENOCARCINOMA; DISEASE PROGRESSION; HUMANS; LUNG; LUNG NEOPLASMS; MICRORNAS; SURVIVAL RATE;

EID: 84870945783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050141     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, et al. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435-1440.
3. Saxman SB, Finch D, Gonin R, Einhorn LH, (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16: 702-706.
4. Hellman S, Weichselbaum RR, (1995) Oligometastases. J Clin Oncol 13: 8-10.
5. Weichselbaum RR, Hellman S, (2011) Oligometastases revisited. Nat Rev Clin Oncol 8: 378-382.
6. Langley RR, Fidler IJ, (2007) Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28: 297-321.
7. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458.
8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH, (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318 discussion 318-321.
9. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG, (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247: 125-135.
10. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250: 440-448.
11. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 113: 37-49.
12. Nichols FC, (2012) Pulmonary metastasectomy. Thorac Surg Clin 22: 91-99, vii.
13. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, et al. (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112: 650-658.
14. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, et al. (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14: 5255-5259.
15. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, et al. (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27: 1579-1584.
16. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, et al. (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45: 823-830.
17. Brown RE, Bower MR, Martin RC, (2010) Hepatic resection for colorectal liver metastases. Surg Clin North Am 90: 839-852.
18. Garcia-Yuste M, Cassivi S, Paleru C, (2010) The number of pulmonary metastases: influence on practice and outcome. J Thorac Oncol 5: S161-163.
19. Abdullah-Sayani A, Bueno-de-Mesquita JM, van de Vijver MJ, (2006) Technology Insight: tuning into the genetic orchestra using microarrays-limitations of DNA microarrays in clinical practice. Nat Clin Pract Oncol 3: 501-516.
20. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
21. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
22. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, et al. (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6: e28650.
23. Kozomara A, Griffiths-Jones S, (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39: D152-157.
24. Nicholson BJ, (1985) On the F-Distribution for Calculating Bayes Credible Intervals for Fraction Nonconforming. IEEE Transactions on Reliability R-34 (3):: 227-228.
25. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414.
26. Fidler IJ, Gersten DM, Riggs CW, (1977) Relationship of host immune status to tumor cell arrest, distribution, and survival in experimental metastasis. Cancer 40: 46-55.
27. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, et al. (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7: 630-636.
28. Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, et al. (2009) Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer 125: 474-482.
29. Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, et al. (2012) Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. J Bone Miner Res 27 (11):: 2387-2398.
30. Lee JH, Welch DR, (1997) Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57: 2384-2387.
31. Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, et al. (2002) Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 19: 233-246.
32. Sousa JF, Espreafico EM, (2008) Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 8: 19.
33. Morgan SC, Parker CC, (2011) Local treatment of metastatic cancer-killing the seed or disturbing the soil? Nat Rev Clin Oncol 8: 504-506.
34. Gupta N, Saleem A, Kotz B, Osman S, Aboagye EO, et al. (2006) Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 12: 3115-3123.
35. Gupta GP, Massague J, (2006) Cancer metastasis: building a framework. Cell 127: 679-695.
36. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
37. Engels B, Rowley DA, Schreiber H, (2012) Targeting stroma to treat cancers. Semin Cancer Biol 22: 41-49.
38. Brennecke J, Cohen SM, (2003) Towards a complete description of the microRNA complement of animal genomes. Genome Biol 4: 228.
39. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
40. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T, (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677.
41. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, et al. (2010) miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140: 652-665.
42. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569.
43. Chen J, Sam L, Huang Y, Lee Y, Li J, et al. (2010) Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures. J Biomed Inform 43: 385-396.
44. Massague J, (2007) Sorting out breast-cancer gene signatures. N Engl J Med 356: 294-297.
45. Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, et al. (2009) STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med 7: 68.
46. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105: 18490-18495.
47. Yang X, Regan K, Huang Y, Zhang Q, Li J, et al. (2012) Single sample expression-anchored mechanisms predict survival in head and neck cancer. PLoS Comput Biol 8: e1002350.
48. Wang W, Peng B, Wang D, Ma X, Jiang D, et al. (2011) Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer 129: 1624-1634.
49. Mehta N, Mauer AM, Hellman S, Haraf DJ, Cohen EE, et al. (2004) Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol 25 (6):: 1677-83.